Dr Mari Järvelaid on patients understanding of medication

Dr Mari Järvelaid, Nordic Estonia Health Centre, Tallinn, Estonia talks about how relapse prevention is an important aim, but few patients really understand the need to keep taking medication when they are at home.

Q: When and how do you first tell a patient that they have schizophrenia?

A: I see mostly patients with first episode psychosis, and frequently they are brought to the hospital by the emergency services. We evaluate the patient in the acute phase, but at that stage we don’t know the diagnosis ourselves. The patient’s history is very likely a long story that we have to follow. 

We may have suspicions. But we don’t come to a diagnosis without seeing how the disease develops. These are people in their late teens or young adults, and they are well educated. By the time I am ready to say it is schizophrenia, the patients very often know that for themselves. Giving them written material is useful in helping them recognise what the problem is. We may help the process by asking if there is anything they see in a booklet that they think is like themselves.

Q: And how are you able to help them?

We will have patients in the hospital for 21 days, perhaps 40 if they are severely ill. Once they are stabilised, we have a team: psychiatrists, clinical psychologists, art therapists.... . And we work with families.

There is still stigma, or course, but that will disappear with time. And compared with decades ago, we have treatments that are effective -- if we can co-operate with patients and they co-operate with us.

Relapse prevention is an important aim, but few patients really understand the need to keep taking medication when they are at home. That is our biggest problem.

Results are better if patients regularly meet a specialist – not necessarily a psychiatrist but someone able to give advice and act as a resource.  

The best outcome is that people with schizophrenia live a normal life. But we all have different capacities. They may need support. But everyone needs somebody.  

The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
Stai abbandonando il sito Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Per accedere alla pagina si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi. La pagina per la quale sta richiedendo l'accesso ospita materiale formativo comunque attinente all'impiego di medicinali prodotti o commercializzati da Lundbeck. Con riferimento al Decreto Legislativo n.219 del 24 aprile 2006 e s.m.i., art. 119, art. 121 comma 1 e art. 124 commi 4 e 8, Lundbeck limita l'accesso ai contenuti presenti nella pagina PIM Academy a medici specialisti e farmacisti ospedalieri.
Per favore, conferma la tua email
Ti abbiamo appena inviato un'e-mail con un link di conferma.
Prima di poter ottenere l'accesso completo, devi confermare la tua email.
Le informazioni su questo sito sono destinate esclusivamente ai professionisti della salute.
Register for access to Progress in Mind in your country